HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT01670071

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

Medication studyAges 20–60Taiwan
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 20 years to 60 years. Other eligibility criteria apply.

Listed locations
Bali Township, Taipei County and 2 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJanuary 2013
Recruitment status
Terminated
Enrollment listed in the registry
17
Sponsor
Johnson & Johnson Taiwan Ltd
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Taiwan
Age range
From 20 Years to 60 Years
Official registry ID
NCT01670071
Official title
Show the full official title

A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Terminated

Bali Township, Taipei County · Hualien City · Kaohsiung City

Checked Official study record (opens in a new tab)

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Johnson & Johnson Taiwan Ltd.

Does this study involve medication?

Yes. The study involves medication, including Paliperidone extended-release and Risperidone immediate-release.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 20 years to 60 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies